CatenaBio’s Post

If you are heading to ELRIG UK Drug Discovery, meet us (Christian Kortleven, Ellen Sandom, Alfonso Tedeschi) at the conference or at the posters below: 1.      Development of Cytokine Release Assays for Human iPSC-Derived Microglia (#249) 2.      Targeted Applications for Investigating Pain and CIPN using iPSC-derived Sensory Neurons (#223) #iPSCmodels #CIPN #painresearch #immunoinflammation

Let’s connect and explore how Cerba Research can support your compound development with world-class specialty and central lab services! #centrallaboratory #clinicaltrial #specialtylab #flowcytometry

I will be attending ELRIG UK's Drug Discovery conference next week with my great colleague Ellen Sandom! Come meet us, whether it is at our posters or during breaks, etc. Our posters are: 1.      Development of Cytokine Release Assays for Human iPSC-Derived Microglia (#249) 2.      Targeted Applications for Investigating Pain and CIPN using iPSC-derived Sensory Neurons (#223)

If you are attending the ASGCT Annual Meeting in Baltimore: Visit my colleague Anna Camus and me at our poster #1778. For the first time we will present our preclinical data on editing and shielding T cells from Alemtuzumab, while preserving CD52‘s expression and anti-phagocytic function. This will protect engineered T cells from Alemtuzumab-mediated lymphodepletion and at the same time prevent increased phagocytosis, which is observed with CD52 knock-out.

Tempus is leveraging the power of multimodal data to introduce the next generation of immunotherapy biomarkers into the clinic. In July, we announced a multimodal algorithm called IPS (immune profile score) that uses DNA+RNA to help inform who may or may not respond to immunotherapy. The test is available today for research use by life science companies, and can help accelerate their work in several meaningful ways: 1. Label Expansion: IPS can be used to identify study participants who may have favorable clinical outcomes when treated with ICI outside of your FDA-approved biomarker labels. 2. Novel ICI Combinations: Use IPS to identify study participants who may have less favorable outcomes when treated with standard ICI and may be candidates for more intensive novel combination therapies. 3. Trial Design: With IPS, partners can refine study participant selection and stratification in clinical trials, enabling more targeted and effective study designs. All made possible by Tempus’ AI-enabled platform.

🥁 Exciting update - our latest preprint is now live!🥁 We are thrilled to share our latest work, in collaboration with the amazing ScreenFect team, titled "Rational Design of Unsaturated, Thioether Ionizable Lipids for Enhanced In vivo mRNA Delivery". This study documented our efficient, rational design and sequential structural optimization of previously identified ionizable lipids, leading in a 200fold improvement of in vivo mRNA delivery, and matching the performance of a market-approved LNP benchmark. A huge thank-you to our incredible co-authors Johanna Simon, Moritz Beck-Broichsitter, Pavel Levkin and Gary Davidson for their crucial contribution! Check out our preprint here: https://lnkd.in/e2DqXMRe

💥 𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐧𝐞𝐰𝐬 𝐟𝐨𝐫 𝐢𝐧-𝐯𝐢𝐯𝐨 𝐦𝐑𝐍𝐀 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐚𝐧𝐝 𝐟𝐮𝐭𝐮𝐫𝐞 𝐯𝐚𝐜𝐜𝐢𝐧𝐞 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭! A terrific collaboration between the teams at ScreenFect GmbH and Merck KGaA has led to the efficient, rational design and sequential structural optimization of previously identified ionizable lipids. 𝐓𝐡𝐢𝐬 𝐰𝐨𝐫𝐤 𝐚𝐜𝐡𝐢𝐞𝐯𝐞𝐝 𝐚 𝐫𝐞𝐦𝐚𝐫𝐤𝐚𝐛𝐥𝐞 𝟐𝟎𝟎-𝐟𝐨𝐥𝐝 𝐢𝐦𝐩𝐫𝐨𝐯𝐞𝐦𝐞𝐧𝐭 𝐢𝐧 𝐢𝐧-𝐯𝐢𝐯𝐨 𝐦𝐑𝐍𝐀 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐲, 𝐦𝐚𝐭𝐜𝐡𝐢𝐧𝐠 𝐭𝐡𝐞 𝐩𝐞𝐫𝐟𝐨𝐫𝐦𝐚𝐧𝐜𝐞 𝐨𝐟 𝐚 𝐦𝐚𝐫𝐤𝐞𝐭-𝐚𝐩𝐩𝐫𝐨𝐯𝐞𝐝 𝐥𝐢𝐩𝐢𝐝 𝐧𝐚𝐧𝐨𝐩𝐚𝐫𝐭𝐢𝐜𝐥𝐞 (𝐋𝐍𝐏) 𝐟𝐨𝐫𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧! A huge thank you to Eleni Samaridou, Moritz Beck-Broichsitter, and Johanna Simon from Merck for the outstanding and exemplary collaboration, which provided valuable insights into lipid development for mRNA delivery. 👍 ScreenFect GmbH, founded 12 years ago by Gary Davidson and me, specializes in lipid synthesis, cell transfection, and gene delivery. The Early Formulation Screening Service of Merck Life Science is a leading hub for mRNA vaccine development, covering everything from LNP formulations and mRNA synthesis to in-vitro evaluations and preclinical scaling up of LNP formulations. The paper "Rational Design of Unsaturated, Thioether Ionizable Lipids for Enhanced In vivo mRNA Delivery" is now available on BioRxiv: https://lnkd.in/eKSz6quf

Tempus is harnessing the power of multimodal data to pave the way for a new era of precision oncology and immunotherapy. In July we announced a multimodal algorithm called IPS (immune profile score) that uses DNA+RNA to help inform who may or may not respond to immunotherapy. The test is available today for research use by life science companies, and can help accelerate their work in several meaningful ways: 1. Label Expansion: IPS can be used to identify study participants who may have favorable clinical outcomes when treated with ICI outside of your FDA-approved biomarker labels. 2. Novel ICI Combinations: Use IPS to identify study participants who may have less favorable outcomes when treated with standard ICI and may be candidates for more intensive novel combination therapies. 3. Trial Design: With IPS, partners can refine study participant selection and stratification in clinical trials, enabling more targeted and effective study designs. The team is currently performing a retrospective, real-world study to evaluate the prognostic and predictive utility of IPS in advanced pan-cancer patients, and will be releasing data later this year. All made possible by Tempus’ AI-enabled platform.

Just completed a great training session on Comet multiomics application with Anjalie Schlaeppi, PhD! Many thanks to the trainers Clément Chevalier from Lunaphore (a Bio-Techne brand) and Racha Fayek from Advanced Cell Diagnostics (ACD) for their expertise and hands-on approach. Looking forward to putting this new knowledge into action! #Multiomics #EPFL

💡 Breaking Down the Latest Findings! 🔬 Our new blog explores how MBL International Corporation's MESACUP™ provides a streamlined and reliable solution for cell culture, diagnostics, and immunological research, supporting your experiments with consistency and ease. Stay updated and learn how this innovation can enhance your research workflows. 👉 Dive into the details: https://hubs.la/Q0300PNR0 #NordicBiosite #MBLMedical #MESACUP